Company: PBH
Filing Date: 2025-06-27
Form Type: DEF 14A
Source: 0001295947-25-000021
Chunk: 52

Company: Prestige Consumer Healthcare Inc.
Filing Date: 2025-06-27
Form: DEF 14A
Chunk 52
---
 award will become fully-vested if within twenty- four (24) months following the change in control, the participant’s employment is terminated by the Company other than for cause, disability or death or the participant resigns for good reason (as such terms are defined in the applicable award agreement). Also, as discussed earlier in this CD&A: • The Compensation and Talent Management Committee approved a “Rule of 62” policy, pursuant to which an employee’s outstanding time-based equity awards will vest, based on actual performance at the end of the 3-year performance period in the case of performance stock units, and in each case prorated based upon the employee’s length of employment during the vesting or performance period, as applicable, in the event he or she with at least six months’ notice retires from the Company with at least five years of service and a total of age and years of service at retirement equal to or greater than 62. • Senior executives may elect to defer settlement of shares until a date set by the executive prior to the LTIP award grant or until six months after termination of employment with the Company. Equity awards will continue to vest pursuant to the terms of the award agreements, but the Company will defer issuing shares until the date set by the executive. Vested but unissued shares will count toward the executive’s stock ownership requirements.

| Prestige Consumer Healthcare Inc. | 2025 Proxy Statement |     | 63 |

Executive Compensation

Summary of Potential Payments upon Termination or Change in Control As described above, each of our named executive officers is entitled to certain benefits in the event his or her employment is terminated under specified circumstances. Circumstances which would trigger payments and/or other benefits to our named executive officers include termination of employment by the Company without cause, termination by the named executive officer for good reason or a change in control of the Company. The following table sets forth payments and benefits that may be received by our named executive officers in the event of termination for specified reasons and/or a change in control of the Company. The following information has been prepared based on the assumption that the named executive officer’s employment terminated, or a change in control of the Company occurred, on March 31, 2025. With respect to the accelerated vesting of equity awards, the value of such acceleration was calculated using $85.97 , the closing price of our common stock on March 31, 2025, the last trading day of fiscal 2025.

| Name         | Termination byCompany WithoutCause